Middle East Biomarker-Based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End Use, By Region, And Segment Forecasts, 2025

The Middle East biomarker-based immunoassays market size was estimated at USD 114.23 million in 2024 and is projected to reach USD 159.25 million by 2033, growing at a CAGR of 3.61% from 2025 to 2033. The market growth is driven by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has led clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring.

Countries such as Saudi Arabia, the UAE, and Kuwait are growing and investing heavily in diagnostic infrastructure and adopting international best practices. A growing trend in the market is the push for deeper partnerships between global diagnostic firms and local healthcare providers. A recent example came in January 2025, when Diatech Pharmacogenetics broadened its work with Merck to give colorectal cancer patients in the Middle East better access to RAS biomarker testing. Moves like this show how strongly the region is leaning toward personalized cancer care. These alliances do not just improve the reach of biomarker assays-they also bring new technologies into local systems and build expertise on the ground. For many international companies, the Middle East is starting to look like one of the most promising areas for growth in precision diagnostics.

The Middle East region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments in countries like Saudi Arabia and the UAE have been putting serious money into diagnostic capacity so they do not have to rely as much on overseas labs. That shift is opening the door for local manufacturing and technology transfer. At the same time, lifestyle-driven diseases are becoming more common, which makes early detection and personalized treatment more important in areas such as oncology, cardiology, and neurology. With more attention now on value-based care, biomarker testing is seen as a practical way to lower costs while still improving patient outcomes.

Strategic collaborations are playing an important role in driving the Middle East biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in the Middle East's expanding clinical research networks. In the meantime, regional organizations are demonstrating their dedication to becoming a center for precision diagnostics innovation by introducing cutting-edge biomarker testing programs that work with international standards, such as King Faisal Specialist Hospital in Saudi Arabia.

Middle East Biomarker-Based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East biomarker-based immunoassays market report based on sample, product, biomarkers, diseases, end use, and region:

Sample Outlook (Revenue, USD Million, 2021 - 2033)
Blood
Tissue
Urine
Saliva
Product Outlook (Revenue, USD Million, 2021 - 2033)
Consumables
Instruments/Analyzers
Reagent & Kits
Services
Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
Safety & toxicity biomarkers
Efficacy & Pharmacodynamic Biomarkers
Predictive & Prognostic Biomarkers
Surrogate/Exploratory Biomarkers
Diseases Outlook (Revenue, USD Million, 2021 - 2033)
Cancer
Cardiovascular Diseases
Neurological Diseases
Immunological Diseases
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
Middle East
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
- Rest of Middle East

Product Code: GVR-4-68040-753-0

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Sample Segment
- 1.2.2. Product Segment
- 1.2.3. Biomarker Segment
- 1.2.4. Diseases Segment
- 1.2.5. End Use Segment
1.3. Information analysis
- 1.3.1. Market formula,tion & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Biomarker
1.9. Total Market: CAGR Calculation
1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape

Chapter 3. Middle East Biomarker-Based Immunoassays Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising demand for precision medicine and personalized therapies
  - 3.2.1.2. Increasing prevalence of chronic and infectious diseases
  - 3.2.1.3. Technological advancements in immunoassay platforms
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High cost of advanced biomarker assays and platforms
3.3. Middle East Biomarker-Based Immunoassays Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Middle East Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Middle East Biomarker-Based Immunoassays Market Sample Movement Analysis
4.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2033 (USD Million)
4.4. Blood
- 4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Tissue
- 4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Saliva
- 4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Urine
- 4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Middle East Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Middle East Biomarker-Based Immunoassays Market Product Movement Analysis
5.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Consumables
- 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Instruments/Analyzers
- 5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Reagent & Kits
- 5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Services
- 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Middle East Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Middle East Biomarker-Based Immunoassays Market Biomarker Movement Analysis
6.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
6.4. Safety & toxicity biomarkers
- 6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Efficacy & Pharmacodynamic Biomarkers
- 6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Predictive & Prognostic Biomarkers
- 6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Surrogate/Exploratory Biomarkers
- 6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Middle East Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Middle East Biomarker-Based Immunoassays Market Diseases Movement Analysis
- 7.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
7.3. Cancer
- 7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
7.4. Cardiovascular Diseases
- 7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Neurological Diseases
- 7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Immunological Diseases
- 7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Others
- 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Middle East Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis

8.1. Segment Dashboard
8.2. Middle East Biomarker-Based Immunoassays Market End Use Movement Analysis
- 8.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.3. Hospitals & Clinics
- 8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
8.4. Diagnostic Laboratories
- 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Research & Academic Institutes
- 8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Others
- 8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Middle East Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis

9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.3. Middle East
- 9.3.1. Oman
  - 9.3.1.1. Key country dynamics
  - 9.3.1.2. Regulatory framework/ reimbursement structure
  - 9.3.1.3. Competitive scenario
  - 9.3.1.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.2. Saudi Arabia
  - 9.3.2.1. Key country dynamics
  - 9.3.2.2. Regulatory framework/ reimbursement structure
  - 9.3.2.3. Competitive scenario
  - 9.3.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.3. UAE
  - 9.3.3.1. Key country dynamics
  - 9.3.3.2. Regulatory framework/ reimbursement structure
  - 9.3.3.3. Competitive scenario
  - 9.3.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.4. Kuwait
  - 9.3.4.1. Key country dynamics
  - 9.3.4.2. Regulatory framework/ reimbursement structure
  - 9.3.4.3. Competitive scenario
  - 9.3.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.5. Qatar
  - 9.3.5.1. Key country dynamics
  - 9.3.5.2. Regulatory framework/ reimbursement structure
  - 9.3.5.3. Competitive scenario
  - 9.3.5.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.6. Rest of Middle East
  - 9.3.6.1. Key country dynamics
  - 9.3.6.2. Regulatory framework/ reimbursement structure
  - 9.3.6.3. Competitive scenario
  - 9.3.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2024
10.4. List of Key Certification Providers/Scheme Owners
10.5. Company Profiles/Listing
- 10.5.1. F. Hoffmann-La Roche AG
  - 10.5.1.1. Company overview
  - 10.5.1.2. Financial performance
  - 10.5.1.3. Product benchmarking
  - 10.5.1.4. Strategic initiatives
- 10.5.2. Abbott
  - 10.5.2.1. Company overview
  - 10.5.2.2. Financial performance
  - 10.5.2.3. Product benchmarking
  - 10.5.2.4. Strategic initiatives
- 10.5.3. Thermo Fisher Scientific Inc
  - 10.5.3.1. Company overview
  - 10.5.3.2. Financial performance
  - 10.5.3.3. Product benchmarking
  - 10.5.3.4. Strategic initiatives
- 10.5.4. Eurofins Scientific
  - 10.5.4.1. Company overview
  - 10.5.4.2. Financial performance
  - 10.5.4.3. Product benchmarking
  - 10.5.4.4. Strategic initiatives
- 10.5.5. QIAGEN
  - 10.5.5.1. Company overview
  - 10.5.5.2. Financial performance
  - 10.5.5.3. Product benchmarking
  - 10.5.5.4. Strategic initiatives
- 10.5.6. Bio-Rad Laboratories, Inc.
  - 10.5.6.1. Company overview
  - 10.5.6.2. Financial performance
  - 10.5.6.3. Product benchmarking
  - 10.5.6.4. Strategic initiatives
- 10.5.7. Siemens Healthineers AG
  - 10.5.7.1. Company overview
  - 10.5.7.2. Financial performance
  - 10.5.7.3. Product benchmarking
  - 10.5.7.4. Strategic initiatives
- 10.5.8. Merck KGaA
  - 10.5.8.1. Company overview
  - 10.5.8.2. Financial performance
  - 10.5.8.3. Product benchmarking
  - 10.5.8.4. Strategic initiatives
- 10.5.9. PerkinElmer Inc.
  - 10.5.9.1. Company overview
  - 10.5.9.2. Financial performance
  - 10.5.9.3. Product benchmarking
  - 10.5.9.4. Strategic initiatives
- 10.5.10. Agilent Technologies, Inc.
  - 10.5.10.1. Company overview
  - 10.5.10.2. Financial performance
  - 10.5.10.3. Product benchmarking
  - 10.5.10.4. Strategic initiatives

Product Code: GVR-4-68040-753-0

List of Tables

Table 1 Middle East biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
Table 2 Middle East biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 3 Middle East biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 4 Middle East biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 5 Middle East biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 6 Middle East biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
Table 7 Saudi Arabia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 8 Saudi Arabia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 9 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 10 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 11 Saudi Arabia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
Table 12 UAE biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 13 UAE biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 14 UAE biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 15 UAE biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 16 Middle East biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
Table 17 Kuwait biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 18 Kuwait biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 19 Kuwait biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 20 Kuwait biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 21 Kuwait biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
Table 22 Oman biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 23 Oman biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 24 Oman biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 25 Oman biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 26 Oman biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
Table 27 Qatar biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 28 Qatar biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 29 Qatar biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 30 Qatar biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 31 Qatar biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Middle East biomarker-based immunoassays market segmentation
Fig. 2 Data analysis biomarkers
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD biomarker modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot - 1
Fig. 14 Segment snapshot - 2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 Porter's five force analysis
Fig. 18 PESTEL analysis
Fig. 19 Middle East biomarker-based immunoassays market: Sample outlook key takeaways
Fig. 20 Middle East biomarker-based immunoassays market: Sample movement analysis
Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Middle East biomarker-based immunoassays market: Product outlook key takeaways
Fig. 26 Middle East biomarker-based immunoassays market: Product movement analysis
Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 Middle East biomarker-based immunoassays market: Biomarker outlook key takeaways
Fig. 32 Middle East biomarker-based immunoassays market: Biomarker movement analysis
Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Middle East biomarker-based immunoassays market: Biomarker outlook key takeaways
Fig. 38 Middle East biomarker-based immunoassays market: Biomarker movement analysis
Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Immunological diseases estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Middle East biomarker-based immunoassays market: End Use outlook key takeaways
Fig. 45 Middle East biomarker-based immunoassays market: End Use movement analysis
Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways
Fig. 51 Regional outlook, 2024 & 2033
Fig. 52 Middle East
Fig. 53 Middle East market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 54 Saudi Arabia key country dynamics
Fig. 55 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 56 UAE key country dynamics
Fig. 57 UAE market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 58 Kuwait key country dynamics
Fig. 59 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 60 Oman key country dynamics
Fig. 61 Oman market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 62 Qatar key country dynamics
Fig. 63 Qatar market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 64 Market differentiators
Fig. 65 Key company market share analysis

Middle East Biomarker-Based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End Use, By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Middle East Biomarker-Based Immunoassays Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Middle East Biomarker-Based Immunoassays Market Variables, Trends & Scope

Chapter 4. Middle East Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis

Chapter 5. Middle East Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis

Chapter 6. Middle East Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis

Chapter 7. Middle East Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis

Chapter 8. Middle East Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis

Chapter 9. Middle East Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis

Chapter 10. Competitive Landscape

List of Tables

List of Figures